Tissue non-sterility fears hit Osteotech as CryoLife toes FDA line
This article was originally published in Clinica
Executive Summary
Eatontown, New Jersey-based tissue provider Osteotech has withdrawn sales estimates of up to $93.5m for 2002 following its suspension of some production this week. The company said it was initiating a voluntary recall of tissue, gathered from 15 donors whose tissue was processed and shipped by Osteotech to two clients, following higher-than-normal sterility failures in finished products.